TOPIC 3 - asthma, COPD, CF Flashcards
manifestations of oxygen toxicity
non productive cough, substernal chest pain, GI upset, dyspnea
compliancy decreases = crackles, hypoxemia, atelectasis, pulmonary edema
interventions for oxygen toxicity
use lowest level of O2 to treat condition, monitor vitals and respiratory assessment
request ABGs when declining
notify MD if PaO2 is greater than 90
hypoxic drive
when PaCO2 increases gradually over time to 60-65, the CO2 receptors no longer function and do not stimulate breathing
interventions for hypoxic drive
use lowest level of O2 (1-3L) with venturi mask
hyperventilation occurs in the first 30 minutes of O2 therapy
oxygen toxicity is defined by
O2 level greater than 50% for more than 24-48 hours
pathophysiology of asthma
reversible airway obstruction from bronchial smooth muscle contraction, vascular congestion, tenacious mucus, and mucosal edema
triggers for asthma
inflammatory - allergies, resp infection, work
irritants - temp change, exercise, strong odors, stress, cold air
others - meds, tobacco, gastric reflux, pollutants, food additives
symptoms related to asthma
labored breathing, wheezing, sleep problems, chest pain, frequent coughing, allergies, common cold, feeling tired
mild asthma attack interventions
prompt relief with inhaled SABA such as albuterol - take 2 to 4 puffs every 20 min
moderate to severe asthma attack interventions
may require ED visit, relief from SABA, oral systemic corticosteroids (oral if moderate, IV if severe), ipratropium, IV magnesium
forced vital capacity
amount of air that can be quickly and forcefully exhaled after maximum inspiration
stepwise approach for managing asthma
1 - quick relief : albuterol, Proventil, Ventolin
2 - flovent
3 - flovent and LABA
controller vs reliever meds
controller - daily meds for persistent asthma, long term control, anti-inflammatory
reliever/quick relief - bronchodilators, used PRN and preventative, oral corticosteroid bursts
long term control anti- inflammatory meds
corticosteroids (inhaled = flovent diskus or HFA) (oral = prednisone)
leukotriene modifiers (montelukast)
anti-IgE (omalizumab)
long term bronchodilators
long acting inhaled B2 agonist (salmeterol)
long acting oral B2 agonist (albuterol)
methylxanthines (theophylline)
quick relief bronchodilators
short acting inhaled B2 agonist (albuterol)
anticholinergics inhaled (ipratropium)
quick relief anti-inflammatory drugs
systemic corticosteroids (prednisone)
COPD
characterized by persistent airflow limitation that is usually progressive
associated with enhanced chronic inflammatory response in the airways and lungs
interventions for COPD
Improve gas exchange & airway clearance
Administer O2
Facilitate deep breathing & coughing to remove secretions
Encourage hydration 2-3L/d
Chest physiotherapy
Prevent or treat infections
Administer bronchodilators, corticosteroids
Small volume nebulizer (SVN), Inhalers
Patient education
Improve nutrition
Improve sleep
Stop smoking
pathophysiology of COPD
hyperplasia of goblet cells - increasing production of mucus
reduced airway diameter - difficulty clearing secretions
loss of ciliary activity
abnormal dilation of distal air space with destruction of alveolar walls
loss of elastic recoil and airflow obstruction
risk factors for COPD
cigarette smoking
environmental exposure
occupational chemical and dusts
air pollution
infections: recurring RTI in childhood, TB
genetics
A1 antitrypsin deficiency
signs and symptoms of COPD
chronic cough with sputum
cyanosis of mucosal membranes
barrel chest
increased resting resp rate
use of accessory muscles
shallow breathing
pursing lips during expiration
EXACERBATING SYMPTOMS
worsening dyspnea
chest tightness
malaise
fatigue
decreased exercise tolerance
complications of COPD
cor pulmonale
acute exacerbations
acute respiratory failure
goals of managing COPD
to alleviate breathlessness and other respiratory symptoms that affect daily activities;
to prevent and reduce the frequency and severity of acute exacerbations;
to minimize disease progression and reduce the risk of morbidity/mortality;
to optimally manage comorbidities (if present) to reduce exacerbations and COPD symptoms related to comorbidities.